U.S. Markets closed
  • S&P 500

    4,349.93
    -6.52 (-0.15%)
     
  • Dow 30

    34,168.09
    -129.64 (-0.38%)
     
  • Nasdaq

    13,542.12
    +2.82 (+0.02%)
     
  • Russell 2000

    1,976.46
    -27.57 (-1.38%)
     
  • Crude Oil

    87.22
    -0.13 (-0.15%)
     
  • Gold

    1,818.90
    -10.80 (-0.59%)
     
  • Silver

    23.57
    -0.24 (-1.00%)
     
  • EUR/USD

    1.1238
    -0.0006 (-0.0562%)
     
  • 10-Yr Bond

    1.8480
    +0.0650 (+3.65%)
     
  • Vix

    31.96
    +0.80 (+2.57%)
     
  • GBP/USD

    1.3455
    -0.0008 (-0.0592%)
     
  • USD/JPY

    114.6680
    +0.0080 (+0.0070%)
     
  • BTC-USD

    37,046.17
    +297.66 (+0.81%)
     
  • CMC Crypto 200

    846.14
    -9.67 (-1.13%)
     
  • FTSE 100

    7,469.78
    +98.32 (+1.33%)
     
  • Nikkei 225

    26,986.43
    -24.90 (-0.09%)
     

Beam Therapeutics Adds To Drug Delivery With $120M GuideTx Buy

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • BEAM
  • Beam Therapeutics Inc (NASDAQ: BEAM) acquires Guide Therapeutics (GuideTx), a developer of nonviral drug delivery vehicles for genetic medicines, in an all-stock deal for $120 million upfront. GuideTx shareholders could also yield up to $320 million more in milestone payments.

  • Beam is betting that adding GuideTx’s lipid nanoparticle (LNP) drug delivery vehicles to the mix will boost its genetic medicines’ reach into new tissues and disease areas.

  • GuideTx’s LNP screening technology tags nanoparticles with DNA barcodes allows hundreds of nanoparticles to be screened in one experiment, in a single animal.

  • So far, GuideTx has identified a library of lipids and lipid formulations that could ramp up the development of gene editing treatments to tissues other than the liver.

  • Price Action: BEAM is down 14.4% at $94.56 in market trading hours on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.